Key Highlights

  • bioAffinity Technologies shares closed up 31% at $12.78.
  • The company is advancing its CyPath Lung platform for post-therapeutic lung cancer monitoring.
  • The goal is to augment standard CT scans with a noninvasive malignancy-risk assessment for survivors.
  • Current diagnostic accuracy metrics reflect early-detection performance rather than independent validation in a recurrence-specific setting.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 31% at $12.78 as the company advances its CyPath Lung platform for post-therapeutic lung cancer monitoring.

What Happened

The company is seeking to augment standard CT scans with a noninvasive malignancy-risk assessment for survivors. While the test shows high diagnostic accuracy, these metrics reflect early-detection performance rather than independent validation in a recurrence-specific setting.

Market Reaction

Shares rose sharply as investors responded to the potential expansion of CyPath Lung's use case into post-treatment monitoring, a large and underserved segment of the lung cancer care pathway.

Outlook

Independent validation of CyPath Lung specifically in a recurrence-monitoring setting, rather than its existing early-detection data, represents the next relevant step to fully support this expanded use case.